Cell and gene therapies offer transformative clinical potential but introduce unique pricing and reimbursement challenges that can delay or restrict patient access. Payers must evaluate therapies characterized by high upfront costs, limited long-term durability data at launch, and small patient populations. Short budget cycles, member churn, reinsurance considerations, public payer constraints, and evolving evidence standards further complicate value assessment and coverage decisions. Treatment centers also face operational and reimbursement risk when delivering high-cost advanced therapies. This workshop provides a practical forum to explore how manufacturers can communicate value credibly, address budget impact concerns, and prepare for real-world reimbursement decision making.

This workshop will gather experts to discuss:

• How to communicate long term clinical and economic value for advanced therapies within payer budget cycles that may span only two to three years
• Framing high upfront costs in ways that strengthen payer confidence despite uncertainty around durability and limited real-world evidence
• Understand how to communicate value to treatment centers managing operational, reimbursement, and site-of-care financial risk when delivering high-cost therapies
• Equip commercial and access teams to support healthcare centres in navigating process bottlenecks such as financial clearance, prior authorization, and revenue cycle risk